Cargando…

Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19

Galectin-3 is a beta-galactoside-binding lectin involved in inflammation and lung fibrosis and postulated to enhance thrombosis. In COVID-19, it is considered to be a prognostic marker of severity. The aim of this study was to evaluate whether galectin-3 is associated with thrombogenicity in COVID-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Puccini, Marianna, Jakobs, Kai, Reinshagen, Leander, Friebel, Julian, Schencke, Philipp-Alexander, Ghanbari, Emily, Landmesser, Ulf, Haghikia, Arash, Kränkel, Nicolle, Rauch, Ursula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178107/
https://www.ncbi.nlm.nih.gov/pubmed/37175392
http://dx.doi.org/10.3390/ijms24097683
_version_ 1785040781344505856
author Puccini, Marianna
Jakobs, Kai
Reinshagen, Leander
Friebel, Julian
Schencke, Philipp-Alexander
Ghanbari, Emily
Landmesser, Ulf
Haghikia, Arash
Kränkel, Nicolle
Rauch, Ursula
author_facet Puccini, Marianna
Jakobs, Kai
Reinshagen, Leander
Friebel, Julian
Schencke, Philipp-Alexander
Ghanbari, Emily
Landmesser, Ulf
Haghikia, Arash
Kränkel, Nicolle
Rauch, Ursula
author_sort Puccini, Marianna
collection PubMed
description Galectin-3 is a beta-galactoside-binding lectin involved in inflammation and lung fibrosis and postulated to enhance thrombosis. In COVID-19, it is considered to be a prognostic marker of severity. The aim of this study was to evaluate whether galectin-3 is associated with thrombogenicity in COVID-19. Patients with moderate-to-severe COVID-19 (COVpos; n = 55) and patients with acute respiratory diseases, but without COVID-19 (COVneg; n = 35), were included in the study. We measured the amount of galectin-3, as well as other platelet and coagulation markers, and correlated galectin-3 levels with these markers of thrombogenicity and with the SOFA Score values. We found that galectin-3 levels, as well as von Willebrand Factor (vWF), antithrombin and tissue plasminogen activator levels, were higher in the COVpos than they were in the COVneg cohort. Galectin-3 correlated positively with vWF, antithrombin and D-dimer in the COVpos cohort, but not in the COVneg cohort. Moreover, galactin-3 correlated also with clinical disease severity, as measured by the SOFA Score. In patients with acute respiratory diseases, galectin-3 can be considered as a marker not only for disease severity, but also for increased hypercoagulability. Whether galectin-3 might be a useful therapeutic target in COVID-19 needs to be assessed in future studies.
format Online
Article
Text
id pubmed-10178107
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101781072023-05-13 Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19 Puccini, Marianna Jakobs, Kai Reinshagen, Leander Friebel, Julian Schencke, Philipp-Alexander Ghanbari, Emily Landmesser, Ulf Haghikia, Arash Kränkel, Nicolle Rauch, Ursula Int J Mol Sci Article Galectin-3 is a beta-galactoside-binding lectin involved in inflammation and lung fibrosis and postulated to enhance thrombosis. In COVID-19, it is considered to be a prognostic marker of severity. The aim of this study was to evaluate whether galectin-3 is associated with thrombogenicity in COVID-19. Patients with moderate-to-severe COVID-19 (COVpos; n = 55) and patients with acute respiratory diseases, but without COVID-19 (COVneg; n = 35), were included in the study. We measured the amount of galectin-3, as well as other platelet and coagulation markers, and correlated galectin-3 levels with these markers of thrombogenicity and with the SOFA Score values. We found that galectin-3 levels, as well as von Willebrand Factor (vWF), antithrombin and tissue plasminogen activator levels, were higher in the COVpos than they were in the COVneg cohort. Galectin-3 correlated positively with vWF, antithrombin and D-dimer in the COVpos cohort, but not in the COVneg cohort. Moreover, galactin-3 correlated also with clinical disease severity, as measured by the SOFA Score. In patients with acute respiratory diseases, galectin-3 can be considered as a marker not only for disease severity, but also for increased hypercoagulability. Whether galectin-3 might be a useful therapeutic target in COVID-19 needs to be assessed in future studies. MDPI 2023-04-22 /pmc/articles/PMC10178107/ /pubmed/37175392 http://dx.doi.org/10.3390/ijms24097683 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Puccini, Marianna
Jakobs, Kai
Reinshagen, Leander
Friebel, Julian
Schencke, Philipp-Alexander
Ghanbari, Emily
Landmesser, Ulf
Haghikia, Arash
Kränkel, Nicolle
Rauch, Ursula
Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19
title Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19
title_full Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19
title_fullStr Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19
title_full_unstemmed Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19
title_short Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19
title_sort galectin-3 as a marker for increased thrombogenicity in covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178107/
https://www.ncbi.nlm.nih.gov/pubmed/37175392
http://dx.doi.org/10.3390/ijms24097683
work_keys_str_mv AT puccinimarianna galectin3asamarkerforincreasedthrombogenicityincovid19
AT jakobskai galectin3asamarkerforincreasedthrombogenicityincovid19
AT reinshagenleander galectin3asamarkerforincreasedthrombogenicityincovid19
AT friebeljulian galectin3asamarkerforincreasedthrombogenicityincovid19
AT schenckephilippalexander galectin3asamarkerforincreasedthrombogenicityincovid19
AT ghanbariemily galectin3asamarkerforincreasedthrombogenicityincovid19
AT landmesserulf galectin3asamarkerforincreasedthrombogenicityincovid19
AT haghikiaarash galectin3asamarkerforincreasedthrombogenicityincovid19
AT krankelnicolle galectin3asamarkerforincreasedthrombogenicityincovid19
AT rauchursula galectin3asamarkerforincreasedthrombogenicityincovid19